IGI Logo

Macleods Pharmaceuticals has filed draft red herring prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI) to raise Rs 5000 crore through an initial public offering (IPO).

The initial share-sale is entirely an offer-for-sale (OFS) of up to 6.05 crore equity shares by promoters. Since the public issue is an OFS, the selling shareholders will be entitled to the entire proceeds of the offer and the company will not receive any proceeds from the public issue. Kotak Mahindra Capital Company, Citigroup Global Markets India, Edelweiss Financial Services, ICICI Securities and Nomura Financial Advisory and Securities (India) are the book running lead managers to the IPO.

Macleods is engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment.